Peptide Compounding Under USP 795 and 797: Documentation

Which USP Chapter Governs Your Peptide?

ການສັງເຄາະ Peptide The scope decision hinges on whether the finished preparation must be sterile at the point of administration — not on whether the starting material is a peptide, a biologic, or a small molecule.

USP General Chapter <795> for nonsterile compounding applies when the preparation is not required to be sterile at administration: most oral liquids, dry powder fills, topical solutions, and lyophilized research stocks used exclusively for in vitro work. USP General Chapter <797> for sterile compounding applies when the preparation must be free of viable microorganisms and meet endotoxin limits at the point of administration — injectables, ophthalmics, intrathecal preparations, and any route where contamination creates direct patient or animal safety risk.

The practical implication for procurement is that route and form must appear in the purchase order — not inferred from the sequence. A supplier who does not ask about intended use before quoting cannot produce a chapter-specific documentation package, because the requirements differ substantially across rows in the table above. Documenting that conversation in writing protects both parties when the lot is reviewed downstream.

Identity Documentation: What “Confirmed” Actually Means for Custom Sequences

Under USP compounding logic, identity confirmation is categorically distinct from purity assessment. Identity answers a categorical question — is this the correct molecule? — while purity answers a quantitative one — how much of the correct molecule is present? Citing only HPLC data as identity evidence is a documentation error that inspectors trained in compounding standards will flag as a matter of routine.

Mass Spectrometry as Primary Identity Evidence

For custom and modified peptides, ESI-MS or MALDI-TOF is the accepted primary method for identity confirmation. The acceptance criterion for standard custom sequences on unit-resolution instruments is an observed [M+H]⁺ or multiply-charged [M+nH]ⁿ⁺ ion within ±0.5 Da of the theoretical monoisotopic mass. For high-resolution ESI-MS data, the criterion tightens to ��2 ppm.

The CoA must report three items, not one: the theoretical mass, the observed mass, and the measured delta. A “pass” statement with no supporting numerical context is not reproducible and not verifiable by the receiving laboratory’s QC team.

For isotope-labeled or deuterium-enriched peptides used as internal standards, two additional data points are required: the isotope envelope shape must correspond to the theoretical isotopologue distribution for the declared enrichment level, and the Δmass relative to the unlabeled analogue must fall within the expected window. An enrichment claim unsupported by envelope analysis cannot be confirmed by molecular weight alone.

For PEGylated, stapled, or macrocyclic peptides where the molecular weight exceeds reliable MALDI-TOF range or where charge envelopes are diffuse, LC-MS with spectral deconvolution or MS/MS fragment ion confirmation should be specified in the analytical method reference on the CoA. If the supplier’s standard platform cannot accommodate the molecular complexity, that is information the buyer needs before synthesis begins — not after the CoA has been issued.

Chromatographic Identity Confirmation

RP-HPLC functions as an orthogonal, corroborating method — not the primary one. Retention time reproducibility across lots, measured under identical column, mobile phase, and gradient conditions, confirms that the material has the expected hydrophobicity and retention profile. This is particularly useful for detecting epimerization, where a D-residue substitution may produce a compound with the correct molecular weight but shifted retention behavior.

The CoA must specify: retention time of the main peak, column stationary phase and dimensions, particle size, mobile phase composition (both aqueous and organic components), gradient program, flow rate, column temperature if controlled, and detection wavelength. A retention time without method context cannot be reproduced and therefore provides no confirmatory value.

The counterion form introduces a systematic effect that is rarely disclosed without asking. Peptides released from Fmoc SPPS with residual TFA counterion absorb at 214 nm and can produce inflated purity percentages by area normalization relative to the same peptide as the acetate salt. If a lot will be used in cell-based assays — where residual TFA is cytotoxic — the CoA should explicitly confirm counterion exchange and specify the final salt form. This detail belongs in the MFR and the CoA, not in a post-receipt email thread.

Purity Standards and CoA Requirements for Modified Peptides

Defining the Acceptance Criteria Before Synthesis Begins

The most avoidable source of lot rejection in custom peptide procurement is a purity specification that was not agreed upon before synthesis commenced. For standard research-grade batches, ≥95% purity by RP-HPLC area normalization is a widely applied acceptance threshold. For material destined for sterile compounding or IND-enabling use, ≥98% purity by HPLC is the industry-typical expectation, though the applicable specification should be documented in the quality agreement rather than assumed. These are industry-typical practice benchmarks, not chapter-mandated numeric limits — which makes their explicit documentation in a purchase-order specification all the more important.

A complete pre-synthesis purity specification for a complex modified peptide should define: (1) minimum main-peak purity by RP-HPLC, (2) maximum acceptable levels for the most probable degradation products — desaminidation, oxidized species at Met or Trp, Asp-Pro bond hydrolysis products, deletion sequences — (3) the endotoxin limit in EU/mg if the compound will be formulated for sterile use, and (4) counterion form. Writing these down before ordering converts a buyer-preference into a binding quality agreement. Establishing them after delivery converts a buyer’s disappointment into a supplier’s negotiating position.

What a Compliant CoA Must Contain

A CoA that does not include the following fields cannot serve as a complete qualification record under USP compounding documentation logic:

A CoA missing any field in this table is incomplete for compounding-level documentation purposes. The appropriate action is to request the missing data before accepting the lot — not to annotate the gap in the receiving record and proceed.

⚠️ຄຳເຕືອນ: Accepting an incomplete CoA and documenting the gap in your IMA record does not close the gap for audit purposes. It creates a traceable acknowledgment that the incoming material standard was knowingly not met.

Storage Conditions, Beyond-Use Dating, and the Stability Data Behind Them

Beyond-use dating is one of the most frequently misunderstood concepts at the supplier-buyer interface. BUD is not expiration dating. Expiration dating is assigned by the original manufacturer under ICH Q1A-compliant stability studies and reflects validated shelf life. BUD is calculated from the date or time of compounding and reflects how long the preparation is expected to retain its composition under specified storage conditions, as established conservatively by the compounder (ASHP, The Pharmacist Guide to Assigning a Beyond-Use Date).

The governing rule for BUD assignment: the BUD must be the earlier of the sterility-based default limit and any shorter limit imposed by a component expiry, ingredient retest date, or documented stability finding. Storage conditions do not extend a BUD beyond ingredient limits — they determine which default BUD category applies when no limiting component constraint exists.

For non-sterile preparations under <795>, the defaults in the absence of supporting stability data are: aqueous solutions, 14 days at controlled cold temperature; non-aqueous liquids and solid formulations, 6 months. For lyophilized peptide powders handled as non-sterile raw materials, a 6-month frozen BUD is defensible only if the container is sealed, desiccated, in inert atmosphere, and held continuously at −20°C or below. Freeze-thaw cycling resets the risk exposure and should trigger documented reassessment.

For sterile preparations under <797>, extended BUD (beyond the 12-hour room-temperature or 24-hour refrigerated defaults for Category 1 CSPs) requires documented stability data from the actual formulation in the actual container-closure system under the actual storage conditions (USP General Chapter <797> FAQ, 2023). A supplier who quotes a 30-day BUD on a sterile peptide solution without a stability study reference is assigning a number, not a scientifically supported date.

Peptide-specific vulnerabilities relevant to storage and BUD decisions include: oxidation at Met, Cys, and Trp residues under aerobic conditions; Asp-Pro hydrolysis under acidic conditions and at temperatures above controlled room temperature; aggregation in hydrophobic or disulfide-containing sequences on freeze-thaw cycling; and racemization at certain residues under prolonged refrigeration. These vulnerabilities must be stated in the supplier’s technical dossier — not assumed by the buyer — because they directly affect what storage conditions are appropriate and how conservatively the BUD should be set.

Labeling Requirements That Hold Up Under Audit

The minimum label content for a compounded sterile preparation is specified in USP General Chapter <797>: names and amounts or concentrations of all active ingredients, the BUD (as date, or hour and date where the 4-hour administration window applies), storage conditions, the compounder’s identity, and a clear indication that the preparation is compounded. When the preparation is distributed rather than directly administered, the label must also specify the time period within which administration must begin.

For custom research peptides, the label should additionally carry the sequence identifier or abbreviated modification code. This is particularly important for variant libraries, isotopically labeled analogs, or PEGylation-degree variants where visual inspection provides no basis for discrimination. A label that says “Peptide A, 5 mg/mL” when four structurally related peptides are in storage is not audit-ready for a regulated research environment.

For dry peptide powders released as non-sterile raw materials under <795>, the label content required for your incoming material acceptance SOP is the practical standard: ຈໍາ​ນວນ​ຫຼາຍ​, sequence, mass or mole quantity, purity result (or CoA reference number), counterion form, storage temperature and conditions, and a retest or BUD date. A QR code linking to the digital CoA is a best practice — it reduces transcription error and accelerates IMA review — though it is not a chapter requirement.

The Five Analytical Records Every Sterile Compounding Supplier Should Provide

For sterile-grade peptide materials, five record categories create the defensible evidence chain from raw ingredient to released lot. Each serves a distinct quality-system function. Collectively, they answer the question an auditor must ask: was this lot made correctly, by qualified people, in a controlled environment, and released based on complete data?

1. Master Formula Record (MFR). The MFR is the standing procedure: every ingredient by name and grade, quantities, equipment identification, step-by-step synthesis and processing procedure, in-process acceptance criteria, and quality-control checkpoints. For custom peptides, the MFR is synthesis-specific — it references resin loading, coupling cycle parameters, cleavage conditions, and purification method. It is the reference baseline against which any deviation is evaluated. A deviation without an MFR has no context.

2. Compounding Record (CR) / Batch Record. The CR documents what actually happened for a specific lot: operator identity and date, actual quantities and instruments used, equipment identification, environmental conditions at time of preparation, deviations from the MFR and their disposition, and both operator and second-person verification. The CR is distinct from the MFR — it is lot-specific, not procedure-specific. A lot with only an MFR and no CR has no execution record.

3. Personnel Training and Competency Records. USP <797> requires documented competency for all personnel involved in sterile compounding, including gloved fingertip and thumb sampling, media-fill qualification, surface sampling, garbing and cleaning competency, and annual or periodic requalification (ASHP Guidelines on Compounding Sterile Preparations, 2014). Training completion certificates are necessary but not sufficient — documented competency assessment results are required.

4. Environmental Monitoring Log. A classified cleanroom designation is a one-time certification; an environmental monitoring log is the ongoing evidence that conditions inside that classification are being maintained. The log must include viable air sampling and surface sampling results, non-viable particle counts, pressure differential readings, temperature and humidity data, action limits for each monitoring location, and documented corrective actions for every exceedance. A log that shows results without action limits cannot be evaluated; a log that shows only non-viable particle data without viable monitoring is incomplete for <797> compliance. The vendor-level supplier governance framework for raw materials and sterilization provides one model for how environmental monitoring connects to lot release decisions.

5. Analytical Release Records. These are the source data behind the CoA: the full HPLC chromatogram with integration table, the complete MS spectrum with deconvolution where applicable, the LAL endotoxin assay report including the method standard curve, and the sterility test report where the lot was compounded under sterile conditions. Release records must be retained in retrievable form for a minimum period defined by the applicable quality standard — typically at least 3 years for research-grade material. A qualified supplier should be able to produce these records upon request without requiring a formal audit declaration.

Common Documentation Gaps That Fail Inspections

The deficiencies that appear most predictably in peptide supplier documentation reviews are not complex or unusual. They are standard gaps that process-driven quality systems close routinely — and that documentation-light suppliers never close without external pressure. ກ່ຽວກັບ

BUD assigned without stability data. A 30-day or 90-day BUD on a sterile formulation that references no stability study is an unsupported number. Inspectors ask for the supporting data as a first-line query; “standard industry practice” is not an acceptable reference, and “same compound used elsewhere” is not stability data for your formulation.

CoA missing method reference or column specification. A reported HPLC purity of 98.5% cannot be independently verified without the method. Column stationary phase, dimensions, particle size, mobile phase, gradient, flow rate, ອຸນ​ຫະ​ພູມ, and wavelength must all appear on the CoA or in a method reference document cited by the CoA. If the column has changed between lots, that fact must be documented.

Endotoxin limit not stated. For sterile materials, the CoA must state the acceptance limit (ຕົວຢ່າງ:, <1 EU/mg or <0.5 EU/mg, depending on the application), the LAL method variant, and the actual result. A result reported without a stated limit leaves the QA team unable to evaluate whether the lot passed the relevant criterion — which is a failing condition in an audit, regardless of the numerical value.

No corrective action documentation for environmental exceedances. An environmental monitoring log that shows an action-limit exceedance with no subsequent corrective action entry indicates either that no investigation was conducted or that it was not documented. Both are problematic. Investigators treat this as a systemic quality failure rather than a record-keeping lapse.

Identity confirmed by chromatography alone. HPLC retention time can corroborate identity but cannot confirm it for custom sequences. Scrambled sequences, racemized residues, and deletion analogs can co-elute under standard RP-HPLC conditions at the expected retention time. MS data is the only method that provides unambiguous molecular identity confirmation for custom sequences; its absence from the CoA is an identity documentation gap, not a purity issue.

Aligning Supplier Documentation with Your In-House QMS

The documentation requirements above are useful only if they map cleanly to your internal quality management system. The most common failure mode is not the absence of supplier records — it is the format mismatch. CoAs with non-standard field labels, batch records in proprietary formats, or analytical reports citing internal method codes without an external translation create friction at incoming material acceptance and extend review timelines for every lot.

The solution is a quality agreement negotiated before the first purchase order, not in response to the first lot rejection. A quality agreement for peptide materials should specify: the exact fields required on the CoA, the format and naming conventions for batch records, the timeframe for providing raw analytical data on request, the process for communicating post-delivery deviations, and record retention obligations. Once in place, it converts your QMS requirements into binding supplier deliverables rather than post-receipt negotiation points.

Three elements are non-negotiable in any quality agreement, regardless of material grade or order volume: a lot-specific CoA with full method references (not a template with a lot number inserted), raw instrument data available on request within a defined window, and a written deviation disclosure process with notification timelines. Establishing these before synthesis begins eliminates most of the downstream quality disputes that consume project time.

For research teams building or reviewing a supplier qualification program, the practical approach to building peptide vendor continuity before a study begins with the quality agreement structure, not with the first CoA review. The incoming material acceptance SOP cannot function as a quality filter if it is only applied after materials have already been produced to an unaligned standard.

For modified or complex custom sequences — PEGylated peptides, cyclic scaffolds, isotope-labeled internal standards — the analytical method selection for identity and purity confirmation requires discussion before synthesis, not after lot release. The MOL Changes custom peptide synthesis platform provides lot-specific CoAs as a standard deliverable, with HPLC chromatograms, MS spectra, and endotoxin LAL reports available on request through the quality documentation process for sterile-grade material. Research teams that need to confirm the full documentation package before committing to a lot can request a lot-specific data review prior to order placement.

If your incoming peptide documentation requirements are not yet fully defined, or if you are managing the transition from a previous supplier with a different documentation standard, the first practical step is a pre-order technical conversation. Contact the MOL Changes synthesis and QC team to align on CoA field requirements, analytical method specifications, and batch record format before synthesis is initiated — it is significantly faster to establish that alignment in writing before a lot exists than to renegotiate it after.